Abstract
While allergen-specific immunotherapy (AIT) is very efficient in hymenoptera venom (HV)-allergic patients, long-term outcome after finishing AIT is not well investigated, especially regarding mechanisms that are suggested to contribute to allergen-specific tolerance. Here, we analyse the Ves v 5-inhibitory activity of sera from wasp venom-allergic patients using the novel cell-free enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) assay. Compared to pre-AIT, sera from patients undergoing AIT displayed an increased ability to inhibit Ves v 5 binding by IgE antibodies. In contrast, this inhibitory activity was reduced in patients having finished AIT 5-12 years ago. Allergen-blocking capacity correlated with serum concentrations of Ves v 5-specific IgG4 which rose during AIT but almost reached pretreatment levels in patients who had stopped AIT more than 5 years ago. These data raise questions about how long allergen tolerance is maintained in AIT-treated HV-allergic patients and suggest that the ELIFAB assay might be an easy-to-use tool assessing long-term tolerance in patients treated with HV-AIT.
References
Feb 26, 1977·Lancet·J Ring, K Messmer
Jul 1, 1986·Clinical Allergy·R UrbanekD Richards
Jan 1, 1986·International Archives of Allergy and Applied Immunology·A FerranteD H Goh
Dec 1, 1993·The Journal of Allergy and Clinical Immunology·R E Reisman
Apr 3, 1998·The Journal of Allergy and Clinical Immunology·D B GoldenL M Lichtenstein
May 26, 1998·The Journal of Allergy and Clinical Immunology·E Lerch, U R Müller
Oct 31, 2006·Journal of Immunological Methods·Mohamed H ShamjiJames N Francis
Oct 19, 2007·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Arnon Goldberg, Ronit Confino-Cohen
May 31, 2008·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P A WürtzenH Ipsen
Jun 23, 2009·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·E-M VargaS R Durham
Jul 9, 2010·Current Opinion in Allergy and Clinical Immunology·David B K Golden
Jan 22, 2011·The Journal of Allergy and Clinical Immunology·Marija Geroldinger-SimicBarbara Bohle
Nov 15, 2011·Allergy·M H ShamjiS R Durham
Oct 2, 2012·The Journal of Allergy and Clinical Immunology·Christian MöbsWolfgang Pfützner
Jul 6, 2013·The Journal of Allergy and Clinical Immunology·Mohamed H ShamjiStephen J Till
Citations
Apr 26, 2016·Molecular Immunology·Guangqiao ZengBaoqing Sun
Oct 7, 2016·Allergy·F Zellweger, A Eggel
Jul 28, 2017·Allergy·G J SturmA Muraro
Nov 25, 2017·Allergy·L ArztG J Sturm
Jan 4, 2018·Nature Communications·Frederic JabsEdzard Spillner
Jun 26, 2018·PloS One·Pia GattingerIrene Mittermann
Sep 10, 2019·Frontiers in Immunology·Umit Murat Sahiner, Stephen R Durham
Jan 14, 2018·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S BlankM Ollert
Sep 30, 2015·Current Opinion in Allergy and Clinical Immunology·Zahra Aryan, Nima Rezaei
Mar 12, 2020·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Wenping WangYifan Guo
Nov 17, 2020·Frontiers in Immunology·Simon BlankMaria Beatrice Bilò
Nov 25, 2021·Immunotherapy·Haifeng ZhongPeter Adler Würtzen
Dec 1, 2021·Immunotherapy·Peiyan ZhengBaoqing Sun